Clinical Study

Nrg Lu-003: A Biomarker Driven Protocol For Previously Treated Alk-Mutation Positive Non-Squamous, Non-Small Cell Lung Cancer - A Nci-Nrg Alk Master Protocol

Posted Date: Feb 5, 2020

  • Investigator: Emily Daugherty
  • Specialties: Cancer, Lung Cancer, Oncology, Pulmonary Diseases, Radiation Oncology
  • Type of Study: Drug

The purpose of this study is to assess whether ALK mutations in non-small cell lung cancers, which are usually associated with drug resistance, are prognostic for a response to ALK inhibitor therapy and to evaluate objective responses of patients with specific genetic alterations treated with crizotinib targeted therapy.


Stage Iv Alk-Positive Adenocarcinoma Non-Small Cell Lung Cancer 18 Years Or Older With Progressive Disease


Lung Cancer, Non-Small Cell Lung Cancer, Alk Mutations

For More Information:

Uc Cancer Center